Background: Recognizes a protein of 33-36kDa, identified as the Excision Repair Cross Complementing (ERCC1). The mammalian ERCC1-encoded polypeptide is required for nucleotide excision repair (NER) of damaged DNA and is homologous to Saccharomyces cerevisiae RAD10, which functions in repair and mitotic intrachromosomal recombination. The structure-specific ERCC1/XPF endonuclease complex is implicated in the repair of two distinct types of lesions in DNA: NER for UV-induced lesions and bulky chemical adducts; and recombination repair of the very genotoxic interstrand cross-links. NER mechanism involves dual incisions on both sides of the damage catalyzed by two nucleases. In mammalian cells XPG cleaves 3' of the DNA lesion while the ERCC1-XPF complex makes the 5' incision. Elevated levels of ERCC1 have also been reported in Cisplatin-resistant cells.
Positive Control: A431 or HeLa lysates, human tonsil tissue
Immunogen: Synthetic peptide derived from human ERCC1 protein
Purification Method: Antigen Immunoaffinity Purification
Concentration: See vial for concentration
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide
References: 1. Hayashi T, et al: ERCC1 mutations in UV-sensitive Chinese hamster ovary (CHO) cell lines. Mutat Res 1998;407(3):269-276.2. de Laat WL, et al: DNA structural elements required for ERCC1-XPF endonuclease activity. J Biol Chem 1998;273(14):7835-7842.3. de Laat WL, et al: Mapping of interaction domains between human repair proteins ERCC1 and XPF. Nucleic Acids Res 1998 Sep 15;26(18):4146-4152.4. Lee-Kwon W, et al: Involvement of the Ras/extracellular signal-regulated kinase signalling pathway in the regulation of ERCC-1 mRNA levels by insulin. Biochem J 1998 Apr 15;331 ( Pt 2):591-597.5. Lee-Kwon W, et al: Nucleotide excision repair is not required for the antiapoptotic function of insulin-like growth factor 1. Exp Cell Res 1998;241(2):458-466.6. Li Q, Bostick-Bruton F, Reed E: Effect of interleukin-1 alpha and tumour necrosis factor- alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line. Anticancer Res 1998;18(4A):2283-2287.7. Li Q, Ding L, Yu JJ, Mu C, Tsang B, Bostick- Bruton F, Reed E: Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells. Int J Oncol 1998;13(5):987-992.8. Lin YW, Kubota M, Koishi S, Sawada M, Usami I, Watanabe K, Akiyama Y: Analysis of mutations at the DNA repair genes in acute childhood leukaemia. Br J Haematol 1998;13(4):357-365.9. Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24(5):331-344.10. Rolig RL, Lowery MP, Adair GM, Nairn RS: Characterization and analysis of Chinese hamster ovary cell ERCC1 mutant alleles. Mutagenesis 1998;13(4):357-365.11. Li Q, Tsang B, Bostick-Bruton F, Reed E: Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells. Biochem Pharmacol 1999;57(4):347-353.12. Miura M, et al. Exp Cell Res 1996;226:126-132.
UniProt: P07992
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
English
Deutsch
